PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. - sprookjes - yvandenbroek - TriplyDB

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

http://www.wikidata.org/entity/Q33751939

about

Use of contemporary genetics in cardiovascular diagnosis Challenges to integrating pharmacogenetic testing into medication therapy management Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.An inter-professional approach to personalized medicine education: one institution's experience Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development.Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics.Emerging roles for pharmacists in clinical implementation of pharmacogenomics Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding.Nurses' communication of pharmacogenetic test results as part of discharge care Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.Attitudes of clinicians following large-scale pharmacogenomics implementation.Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study.The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.The impact of genomics on health outcomes, quality, and safety.Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record.Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)Pharmacogenetic biomarkers for predicting drug response.Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project Prediction of atorvastatin plasmatic concentrations in healthy volunteers using integrated pharmacogenetics sequencing.Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio.A brighter future for the implementation of pharmacogenomic testing.Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).A review of consent practices and perspectives for pharmacogenetic testing Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.The impact of the UGT1A1*60 allele on bilirubin serum concentrations.Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.Integrating pharmacogenomics into electronic health records with clinical decision support.

P2860

Q27025306-52E01F04-284C-4A51-B627-A2F90BE98F0F Q28082835-3BAD354D-1657-45C6-A518-2BF9602DE877 Q28083449-818274D1-0877-4222-99A7-CF00118C3D67 Q28552832-A2481CB4-68B0-4326-82EB-FC782299DD57 Q30234897-EDD822CD-D324-4124-8C5B-CE5A9D2B4B4B Q31153959-2F7423E3-DBC1-4CB1-A5C2-898FAF1251BA Q33565033-3201A8CC-BC3D-46D6-BA38-9633F96CCB10 Q33771344-28FAC106-88BB-4A5A-A513-75F631716741 Q33877987-C7039231-C3E8-42F5-BDFA-DF6A349FC6DE Q34302434-E1C3FD7A-6879-49BA-9055-DD3F99F5B169 Q34459885-E039F3E9-BB7C-4735-AF43-859DED86D4B8 Q34624868-4E04C1F8-0734-42F1-8B6D-B0D58BD2A399 Q35317242-E06D9B77-F4C2-4675-88B8-372264CA0E26 Q35762508-5D988130-3E46-42D9-A829-AF1C2D6AE368 Q35809920-32DEECC8-79D3-4AD2-96A9-EAB227AC8EEC Q36166107-6B80435E-24C9-425A-9625-B470B046F26C Q36438790-843D3847-2BE8-4112-86CF-50E3525702CC Q36573086-F06E11A3-9EF6-48D3-8CF7-F313A4D0633D Q36623055-D21B3776-0868-4A86-8CA1-963CFDF17859 Q36794572-B088C7E4-8E88-495E-AC04-6B80321FC410 Q36943659-3E1D826D-9E38-407D-930F-BEB957C10558 Q37047429-45836271-DFC8-4F7D-9484-E9CA23A96346 Q37156736-44720D29-1CD2-4B9A-BE9B-403BCA69CC35 Q37229202-FFC52143-F096-410E-96AE-2A5767F788D3 Q37433329-8A0025B7-AD9A-4F7C-8109-CAF954600383 Q37597647-67CBC853-3144-4126-8FA5-91AFF5197842 Q38214388-9DDA84AB-7250-48FF-B09C-6C19196934A3 Q38286234-65DB7D87-7E23-4BB3-82B4-6D0519EA0840 Q38289596-E77BA6BC-D9CD-45B6-A323-826102F0FE8C Q38615227-337DDE44-7FE7-44C6-A2D5-4D21C336E14B Q38782604-6394AFF0-0B12-4ADE-B575-1729BFDBE8EF Q38822784-F5BD9BD9-F6E2-4C71-8D7C-5506666A3907 Q38826219-D8BC644C-8822-406D-BEAC-FE7DC1853A45 Q38888585-D13FC03B-C081-42F2-848C-7FFC1B5856C0 Q38929949-51AD96BF-765E-4573-923B-4DC34E11FC8F Q38957310-0F38810B-AAB1-4673-99FB-2B015D56D2B9 Q38998163-E7A8A219-227A-443B-B13E-A7C618BF1C53 Q39038260-40216FF3-80EA-4998-B879-5087093FC9AE Q39062032-CA8F9B9B-080E-4B8C-8073-F3A54A42F32B Q39173300-333D8FD7-0B46-41E2-A3CD-704F9E3C176F

P2860

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

http://www.wikidata.org/entity/Q33751939

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@ast

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@en

type

label

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@ast

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@en

prefLabel

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@ast

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@en

P1433

Q33751939-EEBDF0BA-2C36-42C5-873B-0C447B8E5516

P1476

Q33751939-26A8EE00-AB06-459F-A3D7-6A9303E08068

P2093

Q33751939-02C30602-622E-4930-9D23-1CA9A9ED62FD

Q33751939-3699A5DF-3DE0-42F4-BE36-F3E72CF17DC9

Q33751939-380E58E9-353E-4A24-837B-BEF8B444D91B

Q33751939-3D69FBB5-5744-40CF-AD6C-E7EA8B2E6537

Q33751939-420399F6-31B4-4662-9EF9-A80929C4A5B1

Q33751939-4B4EB6DB-1B9C-41AC-BFAD-5333178ACD47

Q33751939-531E1C19-5C86-45A1-AE4E-FCF20E7A3889

Q33751939-54741E12-DD47-45AF-A853-03099E033634

Q33751939-856ED6AC-66B0-40F2-8C79-F5D755F17EED

Q33751939-B11636FB-00EF-4D0F-A5C7-043C90D3C0FF

P2860

Q33751939-00B54908-56B6-4C2B-88AD-6A18C2004238

Q33751939-0BE4B3B7-9A16-4B8E-B969-A456821FFC30

Q33751939-14A51F92-9564-44C5-A375-B46124F648EA

Q33751939-25E44126-C66D-4273-BCF5-75A6E78A3707

Q33751939-27037F48-8F64-4129-8F76-375EA7B13D83

Q33751939-2D940DDB-60D4-4E09-8FC9-075512519D46

Q33751939-3A569EE4-D204-480B-B122-1B2B74F5BA01

Q33751939-4555ECC4-AEAA-4B2D-BFB4-A2407D7478AF

Q33751939-4C5EA3DD-2F8C-4A90-B5E5-1327C6EAB177

Q33751939-5CFB07DB-A7DC-44F7-B29D-CC07C65725A4

P304

Q33751939-96DFCAF8-F510-49F2-A73F-144A2AEC32A5

P31

Q33751939-113EB5D3-EB88-47DF-87EA-19C4CE50BEB1

P356

Q33751939-A3734B66-E3FF-4C97-8893-0222C5543E6F

P433

Q33751939-115BB786-353D-4195-8DE1-A21E1898E06F

P478

Q33751939-9409D5F7-74C5-44B0-9881-5CE372E265D4

P50

Q33751939-C45FF0ED-6795-41B9-A750-ABE40835FFCF

P577

Q33751939-A3B40865-8E22-48D2-810B-AEC03F07762D

P5875

Q33751939-66C83D63-B95B-4BB7-AE14-2F5037F72C00

P698

Q33751939-F5A432A6-8581-4060-943E-F6596C6FDE1D

P932

Q33751939-B2FC4C20-0A4B-4274-901D-B275022060E6

P356

P1433

American Journal of Medical Genetics Part C: Seminars in Medical Genetics

P1476

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

@en

P2093

Aditya H Gaur

http://www.w3.org/2001/XMLSchema#string

Cyrine E Haidar

http://www.w3.org/2001/XMLSchema#string

Donald K Baker

http://www.w3.org/2001/XMLSchema#string

James M Hoffman

http://www.w3.org/2001/XMLSchema#string

Kristine R Crews

http://www.w3.org/2001/XMLSchema#string

Mark R Wilkinson

http://www.w3.org/2001/XMLSchema#string

Mary V Relling

http://www.w3.org/2001/XMLSchema#string

Nancy M Kornegay

http://www.w3.org/2001/XMLSchema#string

Scott C Howard

http://www.w3.org/2001/XMLSchema#string

Ulrich Broeckel

http://www.w3.org/2001/XMLSchema#string

P2860

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm

Incidental findings in genetics research using archived DNA

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

Pharmacogenomics: translating functional genomics into rational therapeutics.

Challenges in the pharmacogenomic annotation of whole genomes.

Pharmacogenetics: from bench to byte--an update of guidelines.

Pharmacogenomics--drug disposition, drug targets, and side effects.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

P304

45-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJMG.C.31391

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

166C

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260717942

http://www.w3.org/2001/XMLSchema#string

P698

24619595

http://www.w3.org/2001/XMLSchema#string

P932

4056586

http://www.w3.org/2001/XMLSchema#string